XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value
March 08, 2024 07:30 ET
|
XOMA Corporation
Raised up to $140 million of non-dilutive non-recourse capital through a royalty-backed loan related to VABYSMO® from funds managed by Blue Owl Capital Received $15.5 million in cash payments related...
XOMA to Present at Upcoming Investor Conferences in March
February 28, 2024 07:30 ET
|
XOMA Corporation
EMERYVILLE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the following...
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right
February 16, 2024 08:00 ET
|
XOMA Corporation
XOMA enters agreement to acquire Kinnate for cash and CVR; Expects to add $9.5M cash to balance sheet upon completion of acquisition
XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition
January 18, 2024 08:30 ET
|
XOMA Corporation
XOMA provided an $8 million non-dilutive royalty capital solution to Talphera XOMA will receive a 15% royalty on all commercial sales and a significant portion of the 75% royalty generated by...
FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx
January 11, 2024 16:05 ET
|
XOMA Corporation
EMERYVILLE, Calif., Jan. 11, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today that based upon the U.S. Food and Drug Administration’s (FDA)...
XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors
January 08, 2024 07:30 ET
|
XOMA Corporation
XOMA appoints Owen Hughes as CEO
XOMA Announces Stock Repurchase Program of up to $50 Million
January 02, 2024 07:30 ET
|
XOMA Corporation
XOMA to repurchase up to $50M of its stock before January 2027. Management actively participating in capital structure to maximize shareholder value.
XOMA Declares Quarterly Preferred Stock Dividends
December 20, 2023 07:30 ET
|
XOMA Corporation
January quarterly dividend payment to XOMAP and XOMAO stockholders of record on 1/3/2024
XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® Royalties
December 19, 2023 07:30 ET
|
XOMA Corporation
Low-cost financing capitalizes on XOMA’s $14 million acquisition of VABYSMO® (faricimab) royalties in 2021 Proceeds expected to be used for stock repurchases and additional royalty and milestone...
XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder Value
November 07, 2023 07:30 ET
|
XOMA Corporation
Received $6.6 million in cash receipts during the quarter related to our growing royalty base and certain development milestones One New Drug Application (NDA) was filed in the third quarter;...